Presentations , October 27-28 2023
Opening introduction: Ryan Fitzpatrick, CEO, MD Education
Session I: Fit AML, Chaired by: Charlie Craddock
Research and progress in AML
Hagop Kantarjian - MD Anderson Cancer Center, Houston, Texas
MRD and treatment decision making in Fit AML,
Felicitas Thol - Hannover Medical School, Hannover, Germany
Genomics and treatment decision making in Fit adult AML,
Paresh Vyas - University of Oxford, UK
Optimising front line management of Fit AML,
Alessandro Isidori - Marche Nord Hospital, Pesaro, Italy
Which patients with high-risk AML should we transplant and how?,
Charlie Craddock - Queen Elizabeth Hospital, Birmingham, UK
Panel Discussion
Session II: Chaired by: Naval Daver
Optimizing frontline therapy for FLT3 mutated AML patients eligible for intensive chemotherapy,
Gesine Bug - University Hospital Frankfurt, Germany
Treatment of APML in 2023,
Steve Knapper - Cardiff University, UK
Addressing inequity of outcomes and accessing patients with AML,
Pramila Krishnamurthy - King’s College Hospital NHS, Foundation Trust
Mechanisms of resistance and novel combinations with venetoclax based therapies in AML,
Naval Daver - MD Anderson Cancer Center, Houston, Texas
Panel Discussion
Independent educational discussion supported by Astellas
Session III: Chaired by: Alessandro Isidori
Research and progress in ALLL,
Hagop Kantarjian - MD Anderson Cancer Center, Houston, Texas
Novel approaches to treatment of TP53 mutated AML,
Emma Searle - Christie Hospital, Manchester, UK
Menin inhibitors,
Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA
Immunotherapeutic strategies in AML,
Sara Ghorashian - University College London
Optimising transplant outcome,
Alessandro Rambaldi - University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Panel Discussion
Session IV: Chaired by: Charlie Craddock & Naval Daver
Debate: Venetoclax based regimens have an important role to play in the management of Fit adults with AML?
Yes to Venetoclax,
Victoria Potter - King’s College Hospital NHS Foundation Trust, London, UK
Yes to Venetoclax,
Alessandro Rambaldi - University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
No to Venetoclax,
Stéphane de Botton, - Tor Vergata University of Rome, Italy
No to Venetoclax,
Jurjen Versluis - Erasmus University, Rotterdam
Debate discussion
Optimal use of Venetoclax in unfit adults in 2023,
Jessica Altman - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
Optimal use of Venetoclax in unfit adults in 2023,
Priyanka Mehta - University Hospitals Bristol and Weston NHS Foundation Trust, UK
Panel discussion
Session V: Chaired by: Elias Jabbour & Anna Castleton
Research and progress in ALL
Elias Jabbour - MD Anderson Cancer Center, Houston, Texas
Progress and open questions in treatment of AYA ALL
Christina Peters - St. Anna Children’s Cancer Research Institute, Vienna, Austria
Unmet needs in pediatric ALL
David O’Connor - Great Ormond Street Hospital for Children, UK
MRD in ALL: Clinical Consequences - When and How?,
Nicola Gokbuget - University Hospital Frankfurt, Germany
Panel Discussion
Session VI: Chaired by: Christina Peters & Cristina Papayannidis
Antibodies in MRD+ ALL,
Cristina Papayannidis - Universita di Bologna Italy
Antibodies as “Bridges to SCT” in Ph neg ALL,
Sabine Kayser - Medical Faculty Mannheim, Heidelberg University, Germany
How I treat Ph positive ALL in 2023,
Elias Jabbour - MD Anderson Cancer Center, Houston, Texas
Panel Discussion
Debate: Chaired by: Elias Jabbour, Cristina Papayannidis, Allo SCT in Ph positive ALL: for all patients?
Yes for all patients,
Phillippe Rousselot - Hôpital de Versailles, France
No for all patients,
Sabina Chiaretti - Sapienza University of Rome, Italy
Debate discussion
Independent educational discussion supported by Jazz
Session VII: Chaired by: Sabina Chiaretti & Elias Jabbour
Optimizing first line therapy in elderly Ph neg B- ALL,
Matthias Stelljes - Universitätsklinikum Münster, Germany
Genetics of Ph like ALL,
Ilaria Iacobucci - St. Jude Children’s Research Hospital, USA
Treatment strategies for Ph like ALL,
Anna Castleton - The Christie NHS Foundation Trust, Manchester, UK
Precision Medicine for T-ALL
Jan Cools - KU Leuven, Belgium, Germany
Panel discussion
Session VIII: Chaired by: Sridhar Chaganti & Cristina Papayannidis
Menin inhibitors in r-KMT2A ALL,
Cristina Papayannidis - Universita di Bologna Italy
CAR-T in ALL: present and perspectives,
Claire Roddie - University College London, UK
Metabolism and ALL: therapeutic implications,
Giovanni Martinelli - IRST IRCCS, Meldola FC, Italy
When not to transplant in newly diagnosed ALL,
Sridhar Chaganti - Queen Elizabeth Hospital Birmingham, UK
